Rate Benchmarking
Compare your rates with similar providers.
Select a published rate, define comparable providers, and see where that rate falls in your market.
See a sample rate comparisonHCPCS Q2042 (Kymriah) Fee Schedule
Last Verified: October 2026
Healthcare providers use this code to document and receive reimbursement for visits that address high-level medical decision-making, often including multiple diagnoses or prescription management.
Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
| Key Fact | Detail |
|---|---|
| Service Type | Temporary Codes Other Drugs and Service Fees |
| Complexity Level | High |
| Medicaid Fee Schedule | View Medicaid rates for Q2042 |
| Medicare Payment Limit | $591726.201  |
| WAC Price | Lorem ipsum dolor sit amet consectetur Lorem ipsum dolor sit amet consectetur VisitBuyandBill.com |
National average reimbursement for HCPCS Q2042 by major payers:
$383,848.83
$305,573.60
$515,756.22
$520,431.29
Compare published rates across providers.
Choose a payer to see a sample of rates for HCPCS Q2042.
HCPCS Q2042
5 of 25 sample ratesHigher to lower in this preview
Fred Hutchinson Cancer Center
$1,308,631.37Published rateNnamdi Eze
Tennessee Oncology PLLC
$617,674.00Published rateMike Le
Attigo Infusion Inc
$554,859.68Published rateLeonard Harris
Pediatric Emergency Specialists, PC
$523,452.56Published rateCoram Alternate Site Services, Inc.
$18,240.67Published rate
Get a free rate benchmark for your specialty.
Choose your state and specialty to build a report from payer-published rates.
Use market rates to prepare your payer proposal.
Payer Contract Negotiation
Draft a fee schedule renegotiation letter.
Use your fee schedule and market benchmarks to set target rates and draft a letter for your payer.
See a sample payer proposalHCPCS Q2042 vs. Other Other Drugs and Service Fees Codes
The HCPCS Q2042 code is part of the Temporary Codes services used for Other Drugs and Service Fees. It represents a moderate-complexity encounter and is one of several codes that vary based on time spent, level of medical decision-making, and documentation requirements.
The HCPCS Q2042 code involves more provider time and moderate medical decision-making, unlike lower-level codes that require less time and simpler assessments. It typically includes multiple diagnoses, medication management, or test interpretation, leading to higher reimbursement and more detailed documentation requirements.
| Code | Complexity | Description |
|---|---|---|
| Q2041-HCPCS | High | Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
| Q2042-HCPCS | High | Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
| Q2043-HCPCS | High | Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion |
What is a fee schedule?
A fee schedule is a list of fixed prices that healthcare providers charge for specific services, including HCPCS Q2042. These prices vary depending on payer type (Medicare, Medicaid, private insurance), geographic location, and provider contracts.
Understanding the Q2042 fee schedule helps patients estimate costs and providers optimize billing for accurate reimbursements.
Factors that affect fee schedules
Medicare & Medicaid Rates
Government-set reimbursement amounts
Private Insurance Rates
Negotiated rates between providers and insurance companies
Geographic Location
Costs may be higher in urban areas.
Provider Type
Hospital providers may have different rates than private practice.
FREE SAMPLE MARKET COMPARISON
Let's review your payer contracts side-by-side with the market.
Bring your top codes (like HCPCS Q2042) and we'll show you how you compare in 15 minutes or less.